Men with metastatic prostate cancer (mCRPC) who do not respond to hormone therapy (ADT) or who experience early progression (≤1year) have a poor prognosis. There is no consensus regarding the proper next therapy for these men. Abiraterone Acetate (Zytiga) plus prednisone (AA+P) is an effective treatment for men with chemo-naive mCRPC, but limited data are available for poor ADT responders.

Researchers conducted a study to evaluate the efficacy and safety of AA+P as next treatment for this population. This study is the first to investigate the use of AA+P in poor ADT responders. The study demonstrated a consistent result on PSA response rate with other studies suggesting that AA+P should be considered as an option for initial ADT poor responders.

https://doi.org/10.1016/j.juro.2018.02.618

Joel T. Nowak, MA, MSW wrote this Post. Joel is the CEO/Executive Director of Cancer ABCs. He is a Cancer Thriver diagnosed with five primary cancers - Thyroid, Metastatic Prostate, Renal, Melanoma, and the rare cancer Appendiceal cancer.